These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

278 related items for PubMed ID: 17954189

  • 1. Hepatitis C virus viral load after conversion from tacrolimus to cyclosporine in liver transplant patients: a pilot study.
    Guitard J, Sandres-Sauné K, Kamar N, Ribes D, Faguer S, Esposito L, Lavit M, Muscari F, Péron JM, Lavayssière L, Durand D, Rostaing L.
    Transplant Proc; 2007 Oct; 39(8):2603-5. PubMed ID: 17954189
    [Abstract] [Full Text] [Related]

  • 2. Improved liver function and decreased hepatitis C viral load after tacrolimus was replaced by cyclosporine.
    Lorho R, Turlin B, de Lajarte-Thirouard AS, Camus C, Lakehal M, Compagnon P, Meunier B, Boudjema K, Messner M.
    Transplant Proc; 2005 Oct; 37(6):2871-2. PubMed ID: 16182838
    [Abstract] [Full Text] [Related]

  • 3. Effects of immunosuppressants on the progression of hepatitis C in hepatitis C virus-positive renal transplantation and the usefulness of interferon therapy.
    Nanmoku K, Imaizumi R, Tojimbara T, Nakajima I, Fuchinoue S, Sakamoto N, Watanabe M, Teraoka S.
    Transplant Proc; 2008 Sep; 40(7):2382-5. PubMed ID: 18790241
    [Abstract] [Full Text] [Related]

  • 4. Hepatitis C virus therapy, hepatocyte drug metabolism, and risk for acute cellular rejection.
    Kugelmas M, Osgood MJ, Trotter JF, Bak T, Wachs M, Forman L, Kam I, Everson GT.
    Liver Transpl; 2003 Nov; 9(11):1159-65. PubMed ID: 14586876
    [Abstract] [Full Text] [Related]

  • 5. Impact of tacrolimus versus cyclosporine in hepatitis C virus-infected liver transplant recipients on recurrent hepatitis: a prospective, randomized trial.
    Martin P, Busuttil RW, Goldstein RM, Crippin JS, Klintmalm GB, Fitzsimmons WE, Uleman C.
    Liver Transpl; 2004 Oct; 10(10):1258-62. PubMed ID: 15376310
    [Abstract] [Full Text] [Related]

  • 6. Cyclosporine A: good response for patients affected by autoimmune disorders and HCV infection?
    Manna R, Verrecchia E, Fonnesu C, Giovinale M, De Socio G, Curigliano V, Cerquaglia C, Soriano A, Granata M, Migliore A, Massafra U, Gasbarrini G.
    Eur Rev Med Pharmacol Sci; 2009 Mar; 13 Suppl 1():63-9. PubMed ID: 19530514
    [Abstract] [Full Text] [Related]

  • 7. Hepatitis C virus recurrence after liver transplantation: influence of immunosuppressive regimens on viral load and liver histology.
    Oton E, Barcena R, Castillo M, Barreales M, Blesa C, Moreno-Planas JM, Barrios C, Garrido A, Cuervas V.
    Transplant Proc; 2006 Oct; 38(8):2499-501. PubMed ID: 17097980
    [Abstract] [Full Text] [Related]

  • 8. 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus.
    Levy G, Grazi GL, Sanjuan F, Wu Y, Mühlbacher F, Samuel D, Friman S, Jones R, Cantisani G, Villamil F, Cillo U, Clavien PA, Klintmalm G, Otto G, Pollard S, McCormick PA.
    Liver Transpl; 2006 Oct; 12(10):1464-72. PubMed ID: 17004259
    [Abstract] [Full Text] [Related]

  • 9. Canadian national retrospective chart review comparing the long term effect of cyclosporine vs. tacrolimus on clinical outcomes in patients with post-liver transplantation hepatitis C virus infection.
    Yoshida EM, Lilly LB, Marotta PJ, Mason AL, Bilodeau M, Vaillancourt M.
    Ann Hepatol; 2013 Oct; 12(2):282-93. PubMed ID: 23396740
    [Abstract] [Full Text] [Related]

  • 10. Therapeutic drug monitoring of tacrolimus in cardiac transplant recipients: a comparison with cyclosporine neoral.
    Wang CH, Ko WJ, Chou NK, Wang SS.
    Transplant Proc; 2004 Oct; 36(8):2386-7. PubMed ID: 15561257
    [Abstract] [Full Text] [Related]

  • 11. Amantadine monotherapy is ineffective in the treatment of hepatitis C virus recurrence in the post-liver transplantation setting.
    Muzi F, Orlando G, Ielpo B, Anselmo A, Sabato Ceraldi S, de Liguori Carino N, Manzia T, D'Andria D, Tariciotti L, Angelico M, Tisone G.
    Transplant Proc; 2005 May; 37(4):1705-7. PubMed ID: 15919438
    [Abstract] [Full Text] [Related]

  • 12. Influence of immunosuppression and effect of hepatitis C virus on new onset of diabetes mellitus in liver transplant recipients.
    Sánchez-Pérez B, Aranda Narváez JM, Santoyo Santoyo J, Fernández-Aguilar JL, Suárez Muñoz MA, González-Sánchez AJ, Pérez Daga JA, Ramírez Plaza CP, Carrasco Campos J, Jiménez Mazure C, Becerra Ortíz R.
    Transplant Proc; 2008 Nov; 40(9):2994-6. PubMed ID: 19010171
    [Abstract] [Full Text] [Related]

  • 13. Survival and hepatitis C virus recurrence after liver transplantation in HIV- and hepatitis C virus-coinfected patients: experience in a single center.
    Testillano M, Fernandez JR, Suarez MJ, Gastaca M, Bustamante J, Pijoan JI, Montejo M, Valdivieso A, Ruiz P, Gonzalez J, Ortiz de Urbina J.
    Transplant Proc; 2009 Apr; 41(3):1041-3. PubMed ID: 19376421
    [Abstract] [Full Text] [Related]

  • 14. Repeated steroid pulse therapies in HCV-positive liver recipients: significant risk factor for HCV-related graft loss.
    Bahra M, Neumann UP, Jacob D, Langrehr JM, Neuhaus P.
    Transplant Proc; 2005 May; 37(4):1700-2. PubMed ID: 15919436
    [Abstract] [Full Text] [Related]

  • 15. Impact of immunosuppressive therapy on hepatitis C infection after renal transplantation.
    Kahraman A, Witzke O, Scherag A, Pütter C, Miller M, Dechêne A, Ross SR, Gerken G, Hilgard P.
    Clin Nephrol; 2011 Jan; 75(1):16-25. PubMed ID: 21176747
    [Abstract] [Full Text] [Related]

  • 16. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
    Yu S, He X, Yang L, Ma Y, Zhu X, Ju W, Huang J.
    Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
    [Abstract] [Full Text] [Related]

  • 17. Adenosine deaminase activity in serum of patients with hepatitis -- a useful tool in monitoring clinical status.
    Kaya S, Cetin ES, Aridogan BC, Arikan S, Demirci M.
    J Microbiol Immunol Infect; 2007 Aug; 40(4):288-92. PubMed ID: 17712462
    [Abstract] [Full Text] [Related]

  • 18. Successful treatment of fibrosing cholestatic hepatitis after liver transplantation.
    Cimsit B, Assis D, Caldwell C, Arvelakis A, Taddei T, Kulkarni S, Schilsky M, Emre S.
    Transplant Proc; 2011 Apr; 43(3):905-8. PubMed ID: 21486625
    [Abstract] [Full Text] [Related]

  • 19. Management of living donor liver transplant patients using twice-daily 4-hour intravenous cyclosporine therapy.
    Sato K, Iwane T, Sekiguchi S, Nakamura A, Akamatsu Y, Kawagishi N, Miyagi S, Takeda I, Sato A, Fujimori K, Satomi S.
    Transplant Proc; 2009 Apr; 41(1):229-32. PubMed ID: 19249521
    [Abstract] [Full Text] [Related]

  • 20. Long-term outcomes in liver transplant patients with hepatic C infection receiving tacrolimus or cyclosporine.
    Villamil F, Levy G, Grazi GL, Mies S, Samuel D, Sanjuan F, Rossi M, Lake J, Munn S, Mühlbacher F, Leonardi L, Cillo U.
    Transplant Proc; 2006 Nov; 38(9):2964-7. PubMed ID: 17112875
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.